Encore Wound Care is pleased to announce the acquisition of the wound care division of Pinnacle Care Providers. With this strategic move, Encore significantly expands its specialized wound care services, enhances patient access, and reinforces its position as a leading provider across Ohio.
Health Technology Insights: Verdantas Acquires Independent Solutions to Expand in Western U.S.
Encore’s acquisition of Pinnacle’s wound care division represents a significant step forward in its mission to deliver advanced, bedside wound care across the full range of post-acute care settings. By uniting two clinically driven organizations with shared values and complementary strengths, Encore is expanding access to effective, evidence-based care while driving greater efficiency across its network.
Pinnacle’s established presence in long-term care settings enhances Encore’s geographic reach and clinical capacity. The integration of Pinnacle’s experienced teams and aligned care models will streamline operations, strengthen outcomes, and support Encore’s continued growth as a trusted partner to facilities and patients across Ohio.
“We are excited to welcome the Pinnacle wound care team into the Encore family,” said Neall French, Encore President & Shareholder. “Their clinical excellence and dedication mirror our core values, and this acquisition allows us to deepen the quality of care and operational capabilities we deliver.”
Health Technology Insights: Wilma Empowers ABA Practices with New Patient Management Tools
Dr. Brian McClain, MD, Managing Partner at Pinnacle Care Providers, added, “Encore shares our commitment to delivering high-quality, patient-centered wound care. This partnership brings together two organizations focused on clinical excellence, innovative solutions, and meaningful outcomes. We’re confident that this integration will enhance the value and impact of care for the patients and facilities we serve.”
Together, Encore and Pinnacle are well-positioned to further enhance the wound care experience, delivering accessible, high-quality treatment that drives better outcomes for patients and partners alike.
Health Technology Insights: Transition of Promotional Activities for Allergen Immunotherapy Drug Actair in Japan
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
